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Abstract
Background: Radiotherapy is a critical component of the multidisciplinary management of cancers of the head and
neck. It may comprise the primary curative treatment modality or is used in an adjuvant setting to improve local
control and survival by preventing seeding and reseeding of distant metastases from persistent reservoirs of
locoregional disease. Although considerable advances have been made recently in the fields of radiotherapy,
systemic treatment and surgery for head and neck tumours, locoregional recurrence rates remain high and
treatment side effects may have severe impact on patients’ quality of life.
Magnetic resonance-guided high-intensity focused ultrasound (MRg-HIFU) is a novel technique in the treatment
of cancer that has the potential to improve tumour cure rates and decrease treatment-related toxicity. Clinical
applications of HIFU are being used increasingly for the treatment of several tumour sites, for example uterine
leiomyomas and prostate cancer.
Methods/Design: The pilot study presented here is an initial step toward utilizing MRg-HIFU for head and neck
cancer treatment. The rationale for novel treatment options in head and neck cancer is reviewed as well as emerging
evidence that support the increasing clinical utilization of MRg-HIFU.
Discussion: This pilot study aims to assess safety, toxicity and feasibility of MRg-HIFU treatments to the head
and neck region and to evaluate changes caused by MRg-HIFU within the treated tumour regions based on
post-treatment MRI.
Background
Head and neck cancer
Cancer of the head and neck is the sixth most common
form of cancer diagnosed in the world; increasing inci-
dence of oropharyngeal cancers has been reported in
some regions which is likely linked with human
papillomavirus-associated tumours [1]. Approximately
75 % of patients with cancer of the pharynx present with
locally advanced or metastatic disease [2]. For patients
with locally advanced disease, standard treatment typic-
ally includes a 7-week course of chemoradiotherapy
alone or extensive surgery followed by post-operative
chemoradiotherapy. These curative treatments can cause
potentially severe side effects to the organs of the head
and neck responsible for voice, speech, swallowing, taste
and neurologic functions [3, 4].
The most common cause of initial treatment failure in
patients with locally advanced head and neck cancer is
recurrence at the primary site or in the lymph nodes of
the neck [5, 6]. Despite combined modality treatments,
20–55 % of patients with locally advanced head and neck
cancer will develop locoregional recurrence with overall
survival of approximately 40–60 % [6–8]. Primary
salvage treatments include re-irradiation and/or surgery.
Unfortunately, those treatments are often limited by pre-
vious therapy, patient co-morbidities or the presence of
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distant metastasis. Median survival of patients with
recurrent, metastatic disease is 3–6 months [9].
For patients with incurable disease due to recurrence,
metastasis or severe medical co-morbidites, symptoms
such as neck pain, dysphagia and respiratory difficulties
affect patients’ quality of life. Intermediate doses of pal-
liative radiotherapy have demonstrated response rates of
approximately 50–70 % and improvements in quality of
life but may entail more than 5 weeks of daily treatment
and radiation-induced toxicities [3, 10, 11]. There
remains a need for therapeutic strategies which can im-
prove locoregional control and provide symptom relief
while limiting treatment duration and side effects.
MR-guided HIFU: clinical applications
Magnetic resonance-guided high-intensity focused ultrasound
(MRg-HIFU) is a non-invasive, outpatient modality being in-
vestigated for the treatment of cancer. In MRg-HIFU, a spe-
cially designed transducer is used to focus a beam of
ultrasound energy into a small volume at a specific target site
in the body. The focused beam produces therapeutic heating
(55–90 °C for 20–30 s) in the target field causing protein de-
naturation and cell damage resulting in tissue ablation. The
tissue immediately adjacent to the target is warmed to a lower
temperature which does not cause tissue ablation. Magnetic
resonance (MR) imaging will be used both to focus the ultra-
sound beam on the target field in the neck (the metastatic
lymph node or tumour mass—containing nerves and tumour
vasculature) and to perform real-time thermal mapping in
order to limit the ablative effects on the designated target and
preserve healthy tissue.
Clinical applications of HIFU (which may use MR or other
image guidance) are being used increasingly for the treatment
of uterine leiomyomas and prostate cancer [12–15]. A recent
prospective development study of 42 patients utilized MRI
mapping and trans-rectal HIFU ablation of prostate tumours
while sparing the normal gland tissue. HIFU treatment was
associated with low rates of side effects and good early clinical
control [15]. Early clinical studies have also explored HIFU
techniques for the treatment of a wide array of solid tumour
locations including the liver, kidney, breast, pancreas, bone
and brain [16]. Current and potential intracranial applications
include functional neurosurgery, relief of neuropathic pain,
tumour ablation, drug delivery and thrombolysis [17].
Novel studies underway include a randomized, placebo-
controlled phase III trial using MRg-HIFU to treat essential
tremor and disruption of the blood-brain barrier to
enhance drug delivery [17, 18]. Treatment of bone lesions
including both benign and malignant tumours has been an
active area of investigation. The results of a recently com-
pleted phase III trial demonstrate the utility of MRg-HIFU
as a treatment option for patients with painful bone metas-
tases [19, 20].
To our knowledge, at the time of writing this protocol,
there are no prospective clinical data reported on the use of
MRg-HIFU or other HIFU techniques in the setting of
head and neck cancer. In vivo experiments of MRg-HIFU
in a head and neck cancer mouse model demonstrated evi-
dence of tumour de-vascularization, apoptosis and necrosis
[21]. Horsman and Overgaard performed a meta-analysis
which evaluated all clinical trials in which patients were
randomized to receive radiation alone or radiation with
hyperthermia. Twenty-three trials with 1861 patients were
reviewed, and the odds ratio of locoregional control was in
favour of radiation and hyperthermia (OR (95 % CI) = 1.80
(1.50–2.16)) for all tumour sites combined; in the five stud-
ies that included only head and neck cancer patients, the
results suggest overall improvements when heating was
added to radiotherapy (OR = 2.08 (1.28–3.39)) [16].
A controlled randomized study of interstitial hyper-
thermia and radiotherapy was conducted with the ma-
jority of the tumours located in the head and neck
region [22]. The intended goal of hyperthermia in the
study was to increase radiation sensitivity (maintain
tumour temperature of 42.5 °C for 30 to 60 min); this
regimen would not be expected to produce protein de-
naturation and necrosis associated with HIFU (55–90 °C
for 20–30 s). In that study (which pre-dated the use of
focused ultrasound techniques), there were no signifi-
cant differences detected in treatment toxicity or tumour
response and the authors concluded that ‘substantial
technical improvements in heat delivery and dosimetry’
would be required for future studies [22]. Two other tri-
als comparing radiation alone versus radiation and
hyperthermia (42.5 °C for 30 to 60 min) in head and
neck cancers found a benefit in overall survival [23, 24].
Tumour stage may have been an important factor influ-
encing the response, as in one study, a survival benefit of
adding heat was only seen in the stage III and IV pa-
tients [23], whereas in the other study where a clear
benefit was seen, the patients were all stage IV [24]. Sur-
vival advantage with hyperthermia has been demonstrated
for other tumour types such as the carcinoma of the cer-
vix [25]. A prospective, randomized, multicenter trial in-
vestigating the effect of heat on the radiation response in
tumours of the pelvic region reported that the benefit seen
in the patients was primarily influenced by the large en-
hancement in the cervix group compared with tumours
involving the rectum and bladder where no significant im-
provements were seen [26].
The majority of prior studies examining the use of hyper-
thermia with radiotherapy were completed using interstitial
heating techniques, prior to the development of MR-guided
focused ultrasound. With improvement in target delinea-
tion, real-time thermometry and heat dosimetry MRg-HIFU
may provide more consistent and reproducible clinical
benefits.
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Methods/Design: Hypothesis
MRg-HIFU of head and neck cancer with regional lymph
node involvement is safe and feasible when performed prior
to standard radiotherapy treatments. MRg-HIFU can cause
de-vascularization and necrosis of a target lesion within the
neck as demonstrated by post-treatment MRI.
Primary objectives
The primary aim of this study is to assess safety, toxicity
and feasibility of MRg-HIFU treatments to the head and
neck region delivered prior to palliative radiotherapy.
Secondary objectives
The secondary aim of this study is to assess changes
caused by MRg-HIFU within the treated tumour regions
based on post-treatment MRI.
Inclusion criteria
– Age ≥18 years
– Able to give informed consent
– Weight <140 kg
– Biopsy-proven diagnosis of squamous cell or
undifferentiated carcinoma of the head and neck
region (skin and nasopharynx primarily included)
– Radiologic evidence of metastatic disease involving
the lungs, liver or bone
– Radiologic evidence of neck lymphadenopathy with
at least one target lesion measuring >3 cm in the
largest dimension (recurrent or initial presentation)
– Assessed by the treating radiation/medical
oncologists to undergo palliative radiotherapy and/
or chemotherapy
– Target lesion visible by non-contrast MRI
– Target lesion accessible for MRg-HIFU procedure




– Unable to have contrast-enhanced MRI
scan—standard institutional criteria
– Head and neck surgery (excluding biopsy) ≤6 weeks
prior to study enrolment
– Chemotherapy or other systemic anti-cancer agents
≤6 weeks prior to enrolment
– Previous radiotherapy ≤6 weeks prior to enrolment
– Target lesion involves the skin surface causing
ulceration, bleeding or discharge
– Target lesion circumferentially encompasses major
blood vessels (carotid or jugular)
– Target lesion in contact with a hollow viscera
– Target lesion located in the skull, spine or mandible
– Fibrotic scar along a proposed HIFU beam path
– Orthopaedic implant along a proposed HIFU beam
path or at site of target lesion
– Severe cardiovascular, neurological, renal or
haematological chronic disease
– ECOG (Eastern Cooperative Oncology Group)
performance status ≥3
– Active infection
– Unable to tolerate required stationary position
during treatment
– Allergy to MRI contrast agent or sedation
Preliminary ‘run-in’ study
A preliminary, run-in phase will be completed prior to
initiating the main study. Five patients with newly diag-
nosed head and neck cancer will be recruited from the
Head and Neck Oncology Programme at the study insti-
tution. These patients will have been fully staged with a
previous MRI and undergo standard radiation and
chemotherapy as per standard of care. Patients who vol-
unteer and consent to participate will undergo simula-
tion on the Philips MRI-HIFU system. Simulation will
include adjusting patient position, immobilizing them on
the MRI couch with a customized cushion and an MRI
scan to obtain anatomic and temperature images. Pa-
tients will not receive any thermal treatment throughout
this process. This will help determine the optimal pa-
tient position and ultrasound beam approach for differ-
ent tumour locations. The information gathered from
this run-in phase will aid the optimization of patient
preparation and set-up and workflow for the ablative
treatment.
Study design
The main study is a prospective, pilot, single-centre,
single-arm, non-randomized trial.
It is expected to take up to 12 months for a planned
accrual of 10 patients in the study for MRg-HIFU treat-
ments. Therefore, the entire study accrual period is an-
ticipated to be up to 18 months (5 patients MRI only; 10
patients MRg-HIFU treatment).
Recruitment
Patients will be recruited from the Head and Neck On-
cology Programme at the study institution. Patients
meeting the above inclusion and exclusion criteria will
be informed about the study by their attending phys-
ician. Interested patients will meet with a research assist-
ant and will be given a consent form and have their
questions answered. Patients wishing to participate will
sign the consent form and proceed to baseline data
collection.
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Baseline data collection
A research assistant will collect standard baseline demo-
graphic information from participating patients, as well
as help the patient to fill out the pain questionnaire, and
record total analgesic consumption during the previous
24 h (see Fig. 1 and Table 1).
Baseline blood work
If not already available, participating patients will also at-
tend for baseline blood work (CBC, electrolytes, creatin-
ine, INR, PTT) within 2 weeks prior to the MRg-HIFU
procedure (see Table 1). If the standard institutional
blood work requirements for MR imaging with sedation
are not satisfied, the patient is ineligible and will exit the
study.
Baseline MRI examination
If not already available (≤4 weeks prior to enrolment),
participating patients will undergo MR imaging with IV
contrast of the region of the target lesion (see Fig. 1 and
Table 1). The treating radiation oncologist and radiolo-
gist will identify and measure the target lesion. The pos-
ition of the target in relation to the skin, bone, major
blood vessels, nerves and spinal cord will also be evalu-
ated. If the imaging-related inclusion and exclusion cri-
teria are not satisfied, the patient is ineligible and will
exit the study. If the criteria are satisfied, the patient is
eligible and will proceed to the MRg- HIFU procedure.
MR-guided HIFU device description/overview
Philips MRg-HIFU (Philips Sonalleve) offers the phys-
ician two methods for ablating tissue. A point to point
method allows specific heating of cells drawn within the
treatment area. HIFU ablation is performed with the US
energy adjusted to achieve a tissue heating to 55–90 °C
over a ~30-s time period. The source then moves to a
different non-contiguous location, and HIFU ablation is
repeated. Each individual ‘point’ represents an ablative
region with an elliptical shape with an average diameter
of 4.0 mm and length of 8.1 mm producing a volume of
approximately 0.067 cc [27]. The treatment is delivered
point-by-point until the larger target has been encom-
passed. The second method, a volumetric plan, also al-
lows heating of cells within a treatment area. The
difference is that the transducer applies heat in a con-
tinuous manner to adjacent points in a treatment area.
Heating by this method makes it possible to raise the
temperature not just by ablating point per point but also
as a controlled thermal dose over significantly larger vol-
umes. Volume treatment versus point-by-point substan-
tially reduces treatment time, allowing for complete
target coverage and delivery of optimal thermal dose.
(For this pilot study, a point-by-point method will be
used to treat the target lesion.)
The MRg-HIFU system displays real-time temperature
data overlaid on proton or T2 anatomical images, accu-
mulated thermal dose information in the treated area
and an the ultrasound therapy parameters such as trans-
mitted output power that is used to generate the thermal
dose. Additionally, the operator can use a mouse to se-
lect specific thermal areas to obtain temperature read-
out. The display is updated every 1–2 s with new
information.
The system also offers visual and audible alerts to
inform the operator when an area exceeds the user-
defined critical values. Available user alerts are
when:
1) Temperature elevations occur at critical values, i.e.
at 40 °C, in user-defined warning zone areas
2) A significant drop in transmitted power (10 %)
occurs, or
3) A significant drop in temperature versus time curve
at the focus occurs
4) The cavitation detector reaches a critical level—this
device detects when input ultrasound energy creates
bubble activity and not direct temperature elevation
The ultrasound system will automatically shutdown if:
1) A bubble activity is detected in the US transmission
path
2) The transducer overheats
Fig. 1 The study flowchart of treatments and imaging investigations
provides an overview of the sequence of MRg-HIFU, imaging and
follow-up during the study
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3) Measured output power is higher or substantially
lower than the requested power
4) High levels of reflected power are detected in the
amplifiers
5) Any system control element fails to respond
correctly to a control request
A system shutdown is indicated both by the UI and by
an indicator light on the operator console. After a safety
shutdown or use of a stop button by the patient, a man-
ual reset or another clear intervention by the operator is
required before use of the ultrasound system can be
continued.
MR-guided HIFU procedure
On the procedure day, an IV catheter will be inserted to
deliver MR contrast media and medications such as sed-
ation and analgesics as per standard operating proce-
dures within the MR room (see Fig. 1 and Table 1). In
the MR room, the patients will be asked to lie on the
HIFU patient table inside the MRI magnet. The treating
radiation oncologist and MRg-HIFU operator will locate
the target tissue and mark the volume to be treated
using MRI images.
The operator starts the treatment and monitors the
progress of the treatment with MR thermal and dose
maps to ensure adherence to the treatment plan. Philips
MRg-HIFU (Philips Sonalleve) will be used to ablate the
targeted tumour tissue. A point to point treatment
method will be employed in order to achieve target tis-
sue heating to between 55 and 90 °C over a period of up
to 30 s. The source then moves to a different non-
contiguous location, and HIFU ablation is repeated. This
is done point-by-point until all the points have been
treated. For this initial research study, a margin of 1 cm
between the region of ablation and the adjacent critical
structures will be adhered to. Therefore, the peripheral
margins of the tumour may be untreated. When the
whole planned volume has been treated, the operator
stores the full treatment history. The patients are then
conducted to the recovery room for medical supervision.
Before discharge, follow-up instructions will be given to
the patient. The same MRI device will be used on day 14
after HIFU to perform a standard, contrast-enhanced,
follow-up MRI scan of the head and neck to assess for
changes in the target lesion and the neck, such as de-
creased enhancement or necrosis.
Palliative radiotherapy/chemotherapy
All patients in the study will undergo palliative radio-
therapy and/or chemotherapy. Treatments will begin at
least 14 days after the MRg-HIFU treatment. Palliative
radiotherapy treatment will be administered to the pre-
treatment target lesion and in addition may encompass
other tumour regions of the head and neck. The
prescribed dosage for patients who have not received
previous radiotherapy will be between 50 and 66 Gy over
4–7 weeks; in previously irradiated patients, the dose
will be determined at the discretion of the treating radi-
ation oncologist.
Safety and toxicity assessment
The patient will be assessed by a physician investigator
and clinical research assistant (CRA) on the MRg-HIFU
treatment date, then 1 day, 1 week, 2 weeks, 1 month
and 3 months afterward. The first and third month visits
may coincide with other palliative treatments that occur
after the MRg-HIFU therapy.
At each visit, including the treatment date, the Antici-
pated Adverse Effects Screening Assessment and a Pain/
Analgesics form will be completed by the CRA and
physician. If specific adverse effects are identified, then
the National Cancer Institute Common Toxicity Criteria
(NCI CTCAE 4.03) will be utilized to assign a grade/
score to the severity of the effect. At any follow-up visit
or any other time within 60 days following the MRg-
HIFU treatment, serious adverse experiences (SAE) as
defined in the SAE form will be evaluated by a physician
Table 1 Study investigations, treatments and follow-up summarize the full schedule of patient visits, treatment, imaging and

















Physical examination ✓ ✓ ✓ ✓ ✓ soc ✓ ✓
Blood work ✓ soc
MRI ✓ ✓ ✓ soc
Toxicity/SAE ✓ ✓ ✓ ✓ soc ✓ ✓
Pain and analgesic form ✓ ✓ ✓ ✓ soc ✓ ✓
Toxicity and SAE consists of anticipated adverse events screening, NCI CTCAE v4.03 toxicity score and SAE evaluating form when adverse events meet SAE criteria.
Pain and analgesic: assessment consists of a visual analogue scale (VAS) and HIFU-related pain and analgesic form
soc standard of care, visits and assessments will follow regular institutional practice. XRT radiotherapy treatment, SAE serious adverse experience
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and documented. In addition, any SAE, including death
due to any cause, which occurs to any patient who
entered into this study up to 60 days following the MRg-
HIFU treatment, will be reported within 24 h to Philips
Healthcare (regulatory sponsor), necessary regulatory
agencies, research ethics boards and fellow investigators.
If any patient develops a SAE or grade 4 toxicity, then
no further patient will be treated in the study until the
event has been reviewed by the investigators and
deemed unlikely to be related to the study treatment or
unlikely to recur in future patients.
Feasibility
Feasibility of the procedure will be assessed and recorded
by the following:
– Number of patients who meet clinical eligibility
criteria and are enrolled on study.
– Number of patients who complete the first planning
MRI/number deemed to have an appropriate target
lesion within the neck to proceed to MRg-HIFU.
– Number of patients who attend treatment/
completing the MRg-HIFU ablation session.
– If patients are unable to complete the treatment, the
specific reason will be recorded: e.g. pain associated
with procedure, physical set-up of transducer-skin
coupling, organ motion, critical structure con-
straints, and hyperthermia delivered instead of
HIFU.
– Actual treatment delivered vs. MRI plan: number of
sonications, volume receiving ablative temperature,
formation of any unintended lesions outside of the
planned volume.
– Imaging evidence of anticipated HIFU effects:
pre-treatment MRI parameters compared with
post-treatment day 1 and day 14 within the
target region will assess for decrease in contrast
enhancement (de-vascularization) and increased
T2 signal intensity (necrosis).
Unplanned exit from the study
In addition to the criteria for exit mentioned above, pa-
tients may choose to exit the study at any time.
Statistical methods
Demographic data will be organized with descriptive sta-
tistics. All serious adverse events will be recorded and
reported as described above. Toxicity and feasibility
measures will be summarized for all patients. Given the
small number of patients in this pilot study, no inferen-
tial statistical analysis is planned.
Sample size
The study plans to accrue 10 patients. (An additional of
five patients will have MRI only.) This number is typical
for a phase 1 pilot study in patients with advanced can-
cer to establish safety and feasibility. Based on the ex-
pected number of eligible patients referred to the Head
and Neck Oncology Programme at the study institution,
this number also seems a reasonable target (>25 eligible
patients per year). No previous studies of HIFU for head
and neck cancer are available for direct assessment of
patient risk. The risk of serious adverse events resulting
from the MRg-HIFU is estimated to be low to moderate
as the technology is being used safely for other interven-
tions within other body sites with safe outcomes.
Discussion: Implications of the study
If proven safe, feasible and efficacious, this pilot study may
allow the investigators to proceed with studies involving
larger numbers of patients who have potentially curable
disease. Future studies may examine the use of MRg-HIFU
to enhance standard chemoradiotherapy treatments of
locally advanced, unresectable head and neck tumours.
Potential future applications in the head and neck region
include hyperthermia radiosensitization, combined modal-
ity tumour ablation and thermally activated chemotherapy.
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